Aduro Biotech, Inc. (NASDAQ:ADRO) VP Blaine Templeman sold 3,785 shares of the company’s stock in a transaction on Wednesday, January 11th. The stock was sold at an average price of $11.95, for a total transaction of $45,230.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of Aduro Biotech, Inc. (NASDAQ:ADRO) opened at 12.30 on Friday. The company has a 50 day moving average of $11.71 and a 200-day moving average of $12.95. Aduro Biotech, Inc. has a one year low of $7.26 and a one year high of $23.06. The stock’s market cap is $826.34 million.

Aduro Biotech (NASDAQ:ADRO) last released its earnings results on Wednesday, November 2nd. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by $0.09. Aduro Biotech had a negative net margin of 72.04% and a negative return on equity of 23.45%. The business earned $3.79 million during the quarter, compared to analyst estimates of $3.99 million. During the same period last year, the business posted $0.01 EPS. Aduro Biotech’s revenue was down 79.8% compared to the same quarter last year. On average, analysts anticipate that Aduro Biotech, Inc. will post ($1.35) earnings per share for the current year.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the propert of of Daily Political. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this report can be viewed at http://www.dailypolitical.com/2017/01/14/blaine-templeman-sells-3785-shares-of-aduro-biotech-inc-adro-stock.html.

A number of equities research analysts have recently issued reports on the stock. FBR & Co reaffirmed an “outperform” rating and set a $20.00 target price on shares of Aduro Biotech in a report on Monday, November 14th. Leerink Swann set a $14.00 target price on shares of Aduro Biotech and gave the stock a “buy” rating in a report on Monday, October 24th. Canaccord Genuity set a $30.00 target price on shares of Aduro Biotech and gave the stock a “buy” rating in a report on Monday, October 24th. Finally, Roth Capital reaffirmed a “buy” rating and set a $20.00 target price (down previously from $22.00) on shares of Aduro Biotech in a report on Thursday, October 27th. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. Aduro Biotech has an average rating of “Hold” and a consensus price target of $19.60.

A number of large investors have recently added to or reduced their stakes in ADRO. Vanguard Group Inc. increased its position in Aduro Biotech by 15.3% in the second quarter. Vanguard Group Inc. now owns 1,794,838 shares of the company’s stock valued at $20,300,000 after buying an additional 237,924 shares during the period. BlackRock Fund Advisors increased its position in Aduro Biotech by 5.2% in the third quarter. BlackRock Fund Advisors now owns 1,752,256 shares of the company’s stock valued at $21,781,000 after buying an additional 87,069 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in Aduro Biotech by 21.5% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 621,844 shares of the company’s stock valued at $7,730,000 after buying an additional 110,060 shares during the period. State Street Corp increased its position in Aduro Biotech by 237.9% in the second quarter. State Street Corp now owns 543,514 shares of the company’s stock valued at $6,147,000 after buying an additional 382,654 shares during the period. Finally, Northern Trust Corp increased its position in Aduro Biotech by 9.7% in the third quarter. Northern Trust Corp now owns 375,978 shares of the company’s stock valued at $4,673,000 after buying an additional 33,125 shares during the period. 35.55% of the stock is owned by institutional investors.

About Aduro Biotech

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

5 Day Chart for NASDAQ:ADRO

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.